Citryll

About Citryll

Citryll has translated a deep understanding of the neutrophil extracellular trap (NET) pathway to therapeutically address its central role in a broad range of inflammatory diseases. With a unique dual mode of action, the company’s lead antibody, CIT-013, has reached the clinic by demonstrating a precise and powerful ability to control NETs and NETosis. Citryll is initially developing CIT-013 as a novel drug for rheumatoid arthritis and hidradenitis suppurativa, which may serve as enabling indications for a wide spectrum of inflammatory diseases. The initial clinical trials with CIT-013 are expected to provide the foundation for a new treatment paradigm.

Keywords

• Antibody Development
• Hidradenitis Suppurativa
• Immunology
• Inflammatory Diseases
• Neutrophil Extracellular Traps
• Rheumatoid Arthritis
• Therapeutics Development

Address

• Headquarters

  5349AE OssNoord-Brabant, Netherlands

Team by function

Based on 35 public job profiles as of 4 August 2026.

• Research / R&D17
• Executive / C-Suite5
• Consulting / Advisory2
• Healthcare / Medical2
• Operations2
• Administrative / Office1
• Data / Analytics / Science1
• Finance / Accounting1
• Founder / Owner1
• IT / Infrastructure / Security1
• Marketing1
• Other / Unclassifiable1